参附注射液合用心先安治疗难治性心力衰竭疗效观察

Curative Effect Observation of Shenfu Injection Combined with Meglumine Cyclic Adenylate in Treating Refractory Heart Failure

目的探讨参附注射液合用心先安治疗难治性心力衰竭的临床疗效。方法82例难治性心力衰竭患者随机分为对照组和治疗组。对照组常规治疗(吸氧、利尿剂、洋地黄、血管扩张剂、血管紧张素转换酶抑制剂、控制感染和对症支持疗法)。治疗组在常规治疗基础上,参附注射液40ml加入5%的葡萄糖250 ml,心先安120 mg加入5%葡萄糖250 ml静脉点滴,2周为1个疗程,比较两组心功能的改善情况。结果治疗组心功能有显著改善(P均<0.05),治疗组与对照组比较有明显差异(P<0.05)。结论参附注射液合用心先安治疗难治性心力衰竭疗效明显,安全可靠。

Objective To discuss the clinical curative effect of Shenfu Injection combined with Meglumine Cyclic Adenylate in treating refractory heart failure. Methods 82 cases with refractory heart failure were randomly divided into 2 groups： treatment group and control group. Routine treatment was given to control group, including inhalation of oxygen, application of diurectic, digitalis, vasodilator agent and angiotensin converting enzyme inhibitor, infection control and symptomatic treatment; for treatment group, besides the routine treatment, transfusion of 40ml of Shenfu Injection in 250ml of 5 % glucose and 120rag in 250ml of 5 % glucose were added; the improvement of heart function of the 2 groups was compared. Results The heart function of treatment group improved significantly （ P 〈 0.05）, with an obvious difference from that of control group （ P 〈 0.05 ）. Conclusion Shenfu Injection combined with meglumine Cyclic Adenylate is of obvious effect in treating refractory heart failure, it is safe and reliable.